Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
Atara Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion
Atara Announces Submission of Investigational NDA for ATA3219
Atara and Pierre Fabre Announce Publication of Phase 3 ALLELE Tab-cel® Data
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones
Atara Biotherapeutics Announces $15 Million Registered Direct Offering
Atara Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Atara Biotherapeutics is laying off 73 workers in California at the end of the year, a little less than a month after announcing a restructuring and a failed Phase II trial in multiple sclerosis.